These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 8585979

  • 1. Quantitative detection of amplification of proto-oncogenes in breast cancer.
    Chen Y, Dong J, Lu Y, McGee JO.
    Chin Med J (Engl); 1995 Nov; 108(11):849-54. PubMed ID: 8585979
    [Abstract] [Full Text] [Related]

  • 2. [Amplification and overexpression of c-erbB2 in human breast cancer].
    Chen Y, Dong J, Li C.
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):16-9. PubMed ID: 7656779
    [Abstract] [Full Text] [Related]

  • 3. [Amplification of proto-oncogenes C-myc, C-N-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma].
    Bian M, Fan Q, Huang S.
    Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):406-9. PubMed ID: 7587576
    [Abstract] [Full Text] [Related]

  • 4. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J.
    Cancer Res; 1989 Jun 01; 49(11):3104-8. PubMed ID: 2566377
    [Abstract] [Full Text] [Related]

  • 5. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.
    Neoplasma; 2006 Jun 01; 53(5):393-401. PubMed ID: 17013533
    [Abstract] [Full Text] [Related]

  • 6. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E.
    Cancer Res; 1989 Dec 01; 49(23):6675-9. PubMed ID: 2573420
    [Abstract] [Full Text] [Related]

  • 7. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE, Wallis T, Tabasczka P, Visscher DW.
    Mod Pathol; 2000 Jan 01; 13(1):37-45. PubMed ID: 10658908
    [Abstract] [Full Text] [Related]

  • 8. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
    Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA.
    Oncogene; 1987 Jan 01; 1(4):423-30. PubMed ID: 3330785
    [Abstract] [Full Text] [Related]

  • 9. Oncogene amplification in breast cancer.
    Donovan-Peluso M, Contento AM, Tobon H, Ripepi B, Locker J.
    Am J Pathol; 1991 Apr 01; 138(4):835-45. PubMed ID: 1849359
    [Abstract] [Full Text] [Related]

  • 10. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X.
    Mod Pathol; 2000 Nov 01; 13(11):1238-43. PubMed ID: 11106082
    [Abstract] [Full Text] [Related]

  • 11. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.
    Zhou DJ, Ahuja H, Cline MJ.
    Oncogene; 1989 Jan 01; 4(1):105-8. PubMed ID: 2915899
    [Abstract] [Full Text] [Related]

  • 12. Assessing sequential oncogene amplification in human breast cancer.
    Janocko LE, Lucke JF, Groft DW, Brown KA, Smith CA, Pollice AA, Singh SG, Yakulis R, Hartsock RJ, Shackney SE.
    Cytometry; 1995 Sep 01; 21(1):18-22. PubMed ID: 8529465
    [Abstract] [Full Text] [Related]

  • 13. int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction.
    An HX, Niederacher D, Dominik SI, Kuschel B, Yan H, Dall P, Schnürch HG, Bender HG, Beckmann MW.
    Anticancer Res; 1997 Sep 01; 17(4B):3133-6. PubMed ID: 9329619
    [Abstract] [Full Text] [Related]

  • 14. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ, Frierson HF, Williams ME.
    Mod Pathol; 1993 Nov 01; 6(6):654-9. PubMed ID: 7905628
    [Abstract] [Full Text] [Related]

  • 15. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH, Bièche I, Hacène K, Lidereau R.
    Mod Pathol; 1994 Dec 01; 7(9):900-5. PubMed ID: 7892157
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F.
    Breast Cancer Res; 2005 Dec 01; 7(2):R267-73. PubMed ID: 15743507
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M, Barrois M, Terrier MJ, Spielmann M, Riou G.
    Oncogene Res; 1988 Dec 01; 3(1):21-31. PubMed ID: 2905033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.